Sividon Diagnostics, a subsidiary of Myriad Genetics, is a pioneering startup in the healthcare sector, specifically focusing on breast cancer diagnostics. The company offers EndoPredict, a second-generation breast cancer recurrence test. This test is designed to help healthcare professionals identify patients with a low risk of distant recurrence within 10 years, allowing many to safely forgo chemotherapy.

EndoPredict integrates a 12 Gene Molecular Score with clinical features such as tumor size and lymph node status to provide a comprehensive risk assessment. This test has been validated with data from over 3,500 women and is endorsed by international guidelines including ASCO, ESMO, St. Gallen, and AGO.

Sividon primarily serves healthcare professionals, including oncologists and pathologists, who treat early-stage breast cancer patients. The market it operates in is the medical diagnostics industry, with a specific focus on precision medicine for breast cancer.

The business model of Sividon revolves around the sale of its diagnostic tests to healthcare providers. Revenue is generated through the direct sale of these tests, which are used to guide treatment decisions for breast cancer patients. By providing a reliable and validated test, Sividon helps reduce unnecessary chemotherapy treatments, improving patient quality of life and reducing healthcare costs.

In summary, Sividon Diagnostics is at the forefront of breast cancer diagnostics, offering a cutting-edge test that aids in making informed treatment decisions.

Keywords: Breast Cancer, Diagnostics, EndoPredict, Healthcare, Precision Medicine, Recurrence Test, Oncology, Gene Expression, Risk Assessment, Chemotherapy.